Article

Serum N-Glycosylation in Parkinson’s Disease: A Novel Approach for Potential Alterations

Csaba Váradi 1,*, Károly Nehéz 2, Olivér Hornyák 2, Béla Viskolcz 1 and Jonathan Bones 3,4

1 Faculty of Materials Science and Engineering, Institute of Chemistry, University of Miskolc, 3515 Miskolc, Hungary; bela.viskolcz@uni-miskolc.hu
2 Faculty of Mechanical Engineering and Information Technology, University of Miskolc, 3515 Miskolc, Hungary; aitnehez@uni-miskolc.hu (K.N.); oliver.hornyak@uni-miskolc.hu (O.H.)
3 Characterisation and Comparability Laboratory, NIBRT – The National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Blackrock, Co., Dublin A94 X099, Ireland; jonathan.bones@nibrt.ie
4 School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4 D04 V1W8, Ireland

* Correspondence: kemcsv@uni-miskolc.hu; Tel.: +36308947730

Received: 15 May 2019; Accepted: 12 June 2019; Published: 13 June 2019

Abstract: In this study, we present the application of a novel capillary electrophoresis (CE) method in combination with label-free quantitation and support vector machine-based feature selection (support vector machine-estimated recursive feature elimination or SVM-RFE) to identify potential glycan alterations in Parkinson’s disease. Specific focus was placed on the use of neutral coated capillaries, by a dynamic capillary coating strategy, to ensure stable and repeatable separations without the need of non-mass spectrometry (MS) friendly additives within the separation electrolyte. The developed online dynamic coating strategy was applied to identify serum N-glycosylation by CE-MS/MS in combination with exoglycosidase sequencing. The annotated structures were quantified in 15 controls and 15 Parkinson’s disease patients by label-free quantitation. Lower sialylation and increased fucosylation were found in Parkinson’s disease patients on tri-antennary glycans with 2 and 3 terminal sialic acids. The set of potential glycan alterations was narrowed by a recursive feature elimination algorithm resulting in the efficient classification of male patients.

Keywords: glycosylation; Parkinson’s disease; capillary electrophoresis; label-free quantitation; support vector machine

1. Introduction

Parkinson’s disease (PD) is a long-term neurodegenerative disorder affecting millions of people worldwide with no accurate diagnostic marker [1]. PD is mainly linked with decreased dopamine production in the substantia nigra affecting the motor system [2]. Early symptoms of PD include rigidity, impaired balance and shaking, although dementia, depression, and anxiety can also be formed over time [3]. Due to the lack of an appropriate molecular diagnostic test, identification of PD patients is challenging and is based on the presence or absence of certain clinical features such as bradykinesia and postural instability [4,5]. This highlights the need for an appropriate molecular test that can be used as an alternative and to prevent patients from undergoing time-consuming clinical evaluation periods and facilitate diagnosis of the disease. Glycosylation of human serum proteins is reportedly altered in many inflammatory [6] and malignant diseases [7] and in neurodegenerative disorders such as Alzheimer’s [8] and PD [9]. The process of protein glycosylation is driven by several highly specific enzymes; therefore,
the monitoring of glycosylation changes can provide potential markers of the altered intracellular biochemical processes [10]. The most favourable techniques to analyse protein glycosylation are liquid chromatography (LC) and capillary electrophoresis (CE) with fluorescence (FLR) and/or mass spectrometric (MS) detection [11]. Current LC-FLR methods are usually easily transferable to LC-MS, whereas in CE, modified methods are required due to the need of the non-MS friendly surfactants in CE-LIF (laser-induced fluorescence) [12]. Eliminating these additives from the separation electrolyte can result in the appearance of electro-osmotic flow leading to reduced reproducibility and problematic integration. Surface modification of silica capillaries using a polyethylene oxide non-covalent coating is reportedly an efficient alternative strategy to reduce electro-osmotic flow with acceptable long-term stability [13,14], suggesting a potentially new direction for CE-MS glycomics. The accurate MS-based quantitation of glycans is still challenging due to their structural heterogeneity and complexity. One of the most powerful strategies to quantify MS data is label-free quantitation where the expression of an examined feature can be measured based on the spectrometric signal intensity allowing the comparison of unlimited number of MS runs [15]. The generated data can be analysed by various statistical tests, although specifying the order of relevance of significant alterations can be problematic when the number of significant features is high. Support vector machine-estimated recursive feature elimination (SVM-RFE) is a suitable method for the recognition of relevant features which can improve cluster classification [16]. This method recursively selects the important features at the basis of the classification and evaluates classification accuracy resulting in a cross-validation score. Features with no contribution to accurate classifications are dropped; therefore, only a set of the most significant alterations remains. SVM-RFE has been shown to be a powerful tool in the identification of potential alterations and thus the classification of healthy and disease groups [17]. In this study, a novel CE-MS method was developed for the quantitative analysis of the serum N-glycome using commercially sourced serum samples from control and PD patients. Following development, the human serum N-glycome was characterised by CE-MS/MS in combination with exoglycosidase sequencing. Using the developed dynamic coating approach, 15 controls and 15 PD patient samples were analysed in triplicate and all 90 runs were aligned, normalised, and quantified by Progenesis QI. The exported abundances were used to perform statistical analysis where gender-associated alterations were found in male patients. The significant alterations were further narrowed by SVM-RFE, resulting in a clear classification of male patients.

2. Results and Discussion

2.1. Development of a Dynamic Capillary Coating for Robust CE-MS

In this study, a dynamic capillary coating-based CE-MS method was developed for the analysis of human serum glycosylation. During the associated method development, a specific focus was placed on ensuring that the developed electrolyte for capillary zone-based separations was MS compatible. Optimised parameters included the use of uncoated silica capillaries, with an ammonium acetate-based separation buffer and a capillary rinsing regime to ensure stable and repeatable separations without the requirements for non-MS friendly additives. As a first step, 0.2% polyethylene oxide (PEO, M<sub>v</sub> 300,000) was mixed overnight with our previously developed [18] background electrolyte (30 mM ammonium-acetate, pH 5) and filtered through a 0.2 µm membrane. The capillary conditioning started with a basic wash with 2% v/v aqueous ammonia for 1 min, followed by an acidic wash with 2% v/v acetic acid for 1 min, and subsequent coating with the previously prepared 0.2% PEO 30 mM pH 5 ammonium-acetate for 3 min. Finally, a conditioning step was performed by the background electrolyte wash for 3 min. During all the conditioning steps, the capillary flow was switched to waste while 950 mbar was applied to the inlet vial. After conditioning, 1 min background electrolyte flush and sample injection (100 mbar 10 sec, ≈25 nL) was performed, followed by the application of -30 kV to the capillary for 50 min. Integrating the base peak chromatograms, we found that after each conditioning cycle six experimental runs could be made with high migration time reproducibility, that
is, an average migration time %RSD of 0.65 was calculated for 10 peaks of the maltodextrin ladder (Table S1, Supplementary Materials), while the dynamic coating was stable (Figure S1, Supplementary Materials). After six runs, unwanted peak diffusion could occur (Figure S2, Supplementary Materials) due to the partial loss of the dynamic coating which resulted in a deterioration of migration time reproducibility and unstable current. Therefore, a wash and conditioning cycle was included after every six experimental injects for all subsequent experiments providing high reproducibility. The main advantage of this conditioning method is that regular inexpensive silica capillaries can be used for the analysis in combination with dynamic coating, enabling to bypass the use of PVA (poly-vinyl alcohol)-coated capillaries.

2.2. N-Glycan Structure Identification

The optimised dynamic capillary coating method was applied to characterise 2-AA labelled N-glycans using CE-MS/MS and subsequent exoglycosidase sequencing. Human serum glycans are mainly bi-, tri-, and tetra-antennary complex structures with different levels of sialylation and fucosylation. In order to identify these features, glycans were sequentially digested by α2-3 sialidase recombinant from *Streptococcus pneumoniae*, α2-3,6,8,9 sialidase (*Arthrobacter ureafaciens*), α1-3/4 fucosidase (almond meal), α1-6 fucosidase (bovine kidney), α-galactosidase (coffee bean) and β-galactosidase (jack bean) (Figure 1). Data for each digest was collected in MS/MS mode providing essential fragmentation data of high abundant glycans (Figures S3–8, Supplementary Materials) for structural annotation. Glycan nomenclature was used as previously described [19]. As is shown in Figure 1, most of the A3G3S3 and A2G2S2 structures were found to be α2-3 linked, while A2G2S1 provided similar intensity compared to without digestion. After removing all sialic acids, core- (α1-6) and arm- (α1-3) fucosylated structures were also identified. Finally, the galactosidase digestion resulted in the main bi- (A2), tri- (A3) and tetra-antennary (A4) structures as expected, so no further digestion was needed. All digests were analysed by CE-MS/MS providing potential fragmentation patterns of the parent ions enabling the identification of the individual structures listed in Table 1.

| Digest         | Structure       | Charge State | Experimental Mass | Theoretical Mass | ppm   |
|----------------|----------------|--------------|------------------|------------------|-------|
| Serum_Undigested | A4G4S4         | [M-3H]^-      | 1217.747         | 1217.7564        | 7.7   |
|                | A4FG4S4        | [M-3H]^-      | 1266.4548        | 1266.4424        | 9.8   |
|                | FA4G4S4        | [M-3H]^-      | 1266.4539        | 1266.4424        | 9.1   |
|                | FA4FG4S4       | [M-3H]^-      | 1315.1101        | 1315.1283        | 13.8  |
|                | A3G3S3         | [M-2H]^-      | 1499.0176        | 1499.0244        | 4.5   |
|                | A3FG3S3        | [M-2H]^-      | 1572.0323        | 1572.0534        | 13.4  |
|                | FA3G3S3        | [M-2H]^-      | 1572.0413        | 1572.0534        | 7.7   |
|                | FA3FG3S3       | [M-2H]^-      | 1096.3801        | 1096.3858        | 5.2   |
|                | A4G4S3         | [M-2H]^-      | 1120.7133        | 1120.7246        | 10.1  |
|                | A4FG4S3        | [M-2H]^-      | 1169.4205        | 1169.4106        | 6.9   |
|                | FA4G4S3        | [M-2H]^-      | 1169.4243        | 1169.4106        | 11.7  |
| A2G2S1(α2-3)   | A2FG2S2        | [M-2H]^-      | 1170.9056        | 1170.9106        | 4.3   |
|                | FA2BG2S2       | [M-2H]^-      | 1345.47          | 1345.4792        | 6.8   |
|                | FA2G2S2        | [M-2H]^-      | 1243.9321        | 1243.9396        | 6.0   |
|                | A3G3S2         | [M-2H]^-      | 1335.4711        | 1335.4767        | 4.1   |
|                | A3FG3S2        | [M-2H]^-      | 1426.5069        | 1426.5057        | 0.8   |
|                | FA3G3S2        | [M-2H]^-      | 1426.4907        | 1426.5057        | 10.5  |
| Digest         | Structure                        | Charge State | Experimental Mass | Theoretical Mass | ppm  |
|---------------|----------------------------------|--------------|-------------------|------------------|------|
| FA3FG3S2      | [M-2H]^-                         | 3^-           | 1499.56           | 1499.5346        | 16.9 |
| A4G4S2        | [M-2H]^-                         | 2^-           | 1023.6952         | 1023.6928        | 2.3  |
| M3A1G1S1      | [M-2H]^-                         | 2^-           | 842.81            | 842.79           | 23.7 |
| M4A1G1S1      | [M-2H]^-                         | 2^-           | 923.844           | 923.823          | 22.5 |
| A4FG4S2       | [M-2H]^-                         | 2^-           | 1072.3606         | 1072.3787        | 16.9 |
| FA4G4S2       | [M-2H]^-                         | 2^-           | 1072.3604         | 1072.3787        | 17.1 |
| A2G2S1        | [M-2H]^-                         | 2^-           | 1025.3534         | 1025.3629        | 9.3  |
| A2FG2S1       | [M-2H]^-                         | 2^-           | 1098.3836         | 1098.3919        | 7.6  |
| FA2G2S1       | [M-2H]^-                         | 2^-           | 1098.3812         | 1098.3919        | 9.7  |
| FA2FG2S1      | [M-2H]^-                         | 2^-           | 1171.4225         | 1171.4208        | 1.5  |
| A3G1S1        | [M-2H]^-                         | 2^-           | 1126.8932         | 1126.9026        | 8.3  |
| A3G2S1        | [M-2H]^-                         | 2^-           | 1199.9208         | 1199.9315        | 8.9  |
| M5            | [M-2H]^-                         |              | 676.7294          | 676.7358         | 9.5  |
| M5A1          | [M-2H]^-                         |              | 778.29            | 778.2755         | 18.6 |
| M6            | [M-2H]^-                         |              | 757.7544          | 757.7622         | 10.3 |
| M7            | [M-2H]^-                         |              | 838.7827          | 838.7886         | 7.0  |
| M5A1G1        | [M-2H]^-                         |              | 859.3205          | 859.3019         | 21.6 |
| M8            | [M-2H]^-                         |              | 919.8172          | 919.8151         | 2.3  |
| M9            | [M-2H]^-                         |              | 1000.8345         | 1000.8415        | 7.0  |
| Serum_NAN1    | A2G2S2(a2-6)                     | [M-2H]^-      | 1170.9049         | 1170.9106        | 4.9  |
| Serum_NAN1_ABS| A2G2S1(a2-6)                     | [M-2H]^-      | 1025.3599         | 1025.3629        | 2.9  |
| Serum_NAN1_ABS| A3G3F                           | [M-2H]^-      | 1135.4051         | 1135.4102        | 4.5  |
| Serum_NAN1_ABS| A4G4F                           | [M-2H]^-      | 1317.9564         | 1317.9763        | 15.1 |
| Serum_NAN1_ABS| FA2                             | [M-2H]^-      | 790.7841          | 790.7913         | 9.1  |
| Serum_NAN1_ABS| FA2G1                           | [M-2H]^-      | 871.8089          | 871.8177         | 10.1 |
| Serum_NAN1_ABS| FA2BG1                          | [M-2H]^-      | 973.3743          | 973.3574         | 17.3 |
| Serum_NAN1_ABS| FA2G2                           | [M-2H]^-      | 952.8348          | 952.8441         | 9.8  |
| Serum_NAN1_ABS| FA2BG2                          | [M-2H]^-      | 1054.3739         | 1054.3838        | 9.4  |
| Serum_NAN1_ABS| FA2G1                           | [M-2H]^-      | 798.7831          | 798.7888         | 7.1  |
| Serum_NAN1_ABS| A2G2                            | [M-2H]^-      | 879.8091          | 879.8152         | 6.9  |
| Serum_NAN1_ABS| A3G3                            | [M-2H]^-      | 1062.3607         | 1062.3813        | 10.9 |
| Serum_NAN1_ABS| A4G4                            | [M-2H]^-      | 1244.9375         | 1244.9474        | 8.0  |
| Serum_NAN1_ABS| A1                              | [M-2H]^-      | 616.2136          | 616.2227         | 14.8 |
| Serum_NAN1_ABS| A2                              | [M-2H]^-      | 717.7538          | 717.7624         | 12.0 |
| Serum_NAN1_ABS| A3                              | [M-2H]^-      | 819.2926          | 819.3021         | 11.6 |
| Serum_NAN1_ABS| A4                              | [M-2H]^-      | 920.8359          | 920.8417         | 6.3  |
| Serum_NAN1_ABS| M3                              | [M-2H]^-      | 514.6796          | 514.683          | 6.6  |
2.3. Data Analysis

The relative area percentages were calculated from the normalised abundances of the identified structures. As is shown in Table S2 (Supplementary Materials), 15 structures were significantly different when comparing the controls to the PD patients. One of the main trends between the two groups is the lower level of tri- (A3G3S3, A3G3S2, Figure 2A,B) and tetra-antennary glycans (A4G4S3, A4G4S2, Table S2, Supplementary Materials) with terminal sialic acids in PD. This result is in agreement with a recent study where lower sialylation was found on plasma IgG glycans in PD patients [9]. The lower level of A3G3S3 and A3G3S2 was also significantly different if one (Figure 2C,D) or 2 (Figure 2E,F) fucose residues were attached to the same structure, suggesting increased fucosylation in the disease. Similar alteration was reported in Alzheimer’s disease using lectin chip microarray where Lotus tetragonolobus lectin showed increased fucosylation in diseased patients [20]. To examine the origin of higher fucosylation in PD, control and disease groups were separated into control females, control males, PD females, and PD males resulting in the increase of significant features up to 26 using the Kruskal–Wallis test (Table S2, Supplementary Materials).
To examine the origin of higher fucosylation in PD, control and disease groups were separated into control females, control males, PD females, and PD males resulting in the increase of significant features up to 26 using the Kruskal–Wallis test (Table S2, Supplementary Materials).

Due to the high number of significant alterations, SVM-RFE was applied to both female and male datasets. Analysing females, the highest cross-validation score was 0.63 when 11 features were selected by the algorithm (FA2, FA2BG1S1, FA2FG2S1, FA2G2S1, FA2G2S2, FA3G2S2, FA4G4S3, M4A1G1S1, M5A1G1, M5A1G1S1, M6) resulting in a poor classification as is shown in Figure S10 (Supplementary Materials). In males, 8 structures were selected with a cross-validation score of 0.86, suggesting a clear classification of control and PD groups (Figure 3A). Selected structures were as follows: A4G4S3, A4G4S3(2), FA2BG1S1, FA2G2, FA2G2S1, FA3G1S1, FA3G2S1, and FA3G3S1. As is shown in Figure 3B, the optimal decision tree was created by the evaluation of A4G4S3 and FA2BG1S1 showing efficient classification of control males and PD males. Similar to Figure 2, the sialylation and fucosylation were found to be the most important features. In the first level of the tree, 7 male controls were separated from 13 when the relative area percentage of A4G4S3 was higher than 0.132. The remaining group contained 6 control males and all the 24 PD males which were well distinguished by the evaluation of
FA2BG1S1. When the relative area percentage of this structure was less than 0.238, the patient belonged to the PD group; if it was higher, it was a control patient. The main limitation of this evaluation is that the used structures are low abundant features and the precise quantitation of a structure with 0.1% relative area is challenging, although our main goal was to show the strength of this strategy in the classification of control and diseased patients.

3. Conclusions

A novel dynamic capillary coating strategy was presented in this study for CE-MS glycomics. The developed method was employed to annotate serum N-glycans in combination with exoglycosidase sequencing and MS/MS fragmentation. The identified features were quantified in patient samples by label-free quantitation. Altered levels of sialylation and fucosylation were found to be most significant in PD patients on tri- and tetra-antennary glycans, which were mainly originating from male patients. This alteration was also found to be critical in the classification of control and PD males. Our future target is to examine the efficacy of this classification strategy on a higher number sample set.

4. Materials and Methods

4.1. Chemicals and Reagents

Isopropanol, ammonium-hydroxide, acetic acid, sodium-cyanoborohydride, 2-aminobenzoic acid, dithiothreitol (DTT), iodoacetamide, and 10 kDa molecular weight cut-off (MWCO) centrifugal filters were purchased from Sigma-Aldrich (St. Louis, MO, USA). Exoglycosidase enzymes were obtained from Prozyme (San Francisco, CA, USA).

4.2. Patient Samples

For this study, 15 control (10 females and 5 males, average age 66.8) and 15 PD patient (6 females and 9 males, average age 66.5) serum samples were purchased from Bioreclamation IVT (Westbury, NY, USA).

4.3. N-Glycan Release, Labelling, and Clean-Up

Serum samples were normalised based on their protein concentration using Bradford protein assay. A 250 µg portion of serum samples from each patient was denatured using 8 M urea in 0.1 M tris buffer pH 8.0 (UA solution) and subsequently reduced and alkylated using 10 mM DTT and 55 mM IAA prepared in UA solution. The samples were buffer exchanged into 100 µL of 50 mM ammonium bicarbonate followed by N-glycan release using 500 units of PNGase F (New England Biolabs, Ipswich, MA, USA) overnight at 37 °C. The released glycans were collected from the deglycosylated proteins by
centrifugation through 10 kDa MWCO filters and reduced to dryness using vacuum centrifugation (Thermo Fisher Scientific, Waltham, MA, USA). Glycans were reconstituted in 20 µL of 1% v/v aqueous formic acid to promote hydrolysis of the glycosylamines and reduced to dryness. A 5 µL portion of labelling solution (0.37 M 2-AA containing 1 M NaCNBH₃ in DMSO/acetic acid (70:30)) was added to the dried sugars and incubated at 65 °C for 5 hours. HPLC water (10 µL) was added to the labelled samples and then purified using frontal HILIC (hydrophilic-interaction liquid chromatography) separation on a Thermo Scientific Ultimate 3000 UHPLC system (San Jose, CA, USA) and a 50.0 × 2.1 mm ID, 1.7 µm Waters BEH Glycan amide column (Milford, MA, USA). Samples were loaded onto the column and washed to remove excess 2-AA in 85% v/v acetonitrile. Purified glycans were eluted using 20% v/v aqueous acetonitrile, automatically collected and reduced to dryness using vacuum centrifugation prior to CE-MS analysis.

4.4. CE-MS Analysis

CE-MS experiments were made on an Agilent 7100 capillary electrophoresis system coupled to an Agilent G1607B orthogonal coaxial sheath sprayer and an Agilent 6520 Accurate-Mass Q-TOF mass spectrometer controlled by Mass Hunter B.07.00 (Santa Clara, CA, USA). Samples were injected by pressure (100 mbar, 10 seconds) and electrophoretic separations were performed by a constant voltage of −30 kV. Stable electrospray was supported by a sheath flow of 0.2% v/v ammonium hydroxide in 50% v/v water/isopropanol at 5 µL/min flow rate delivered by an Agilent G1376 capillary pump. During the analysis, 3.2 kV electrospray voltage was applied while the fragmentor voltage offset was 175 V. The drying gas temperature was 250 °C delivered at 5 L/min. Mass spectra were acquired using negative ionisation mode over the range of 500–2000 m/z with 2 GHz digitisation. MS/MS fragmentations were recorded in data-dependent mode across the range of 100–2000 m/z, and 1 precursor ion was selected for fragmentation with the absolute threshold of 200 [18].

4.5. MS Data Alignment and Analysis

Progenesis QI 2.1 (Nonlinear Dynamics, Newcastle, UK) was used for the alignment and normalisation of the 90 CE-MS runs where only doubly and triply charged ions were included. Sensitivity was set to absolute ion intensity and the minimum chromatographic peak width was 0.1 min. Mann–Whitney pairwise comparison and Kruskal–Wallis tests were performed by SPSS version 2.0 (IBM, Armonk, NY, US). Recursive feature elimination and decision trees were generated in Python 3.6, Scikit-learn-0.19.1 (Delaware, DE, US).

Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/12/2220/s1, Figure S1: Reproducibility of 2-AA labeled maltodextrin ladder using dynamic mobile coating, Figure S2: Effect of stable coating on peak diffusion, Figure S3: MS/MS fragmentation of FA2, Figure S4: MS/MS fragmentation of FA2G2, Figure S5: MS/MS fragmentation of FA2G2S2, Figure S6: MS/MS fragmentation of A2, Figure S7: MS/MS fragmentation of A2G2, Figure S8: MS/MS fragmentation of A2G2S2, Figure S9: Increased fucosylation was originating from PD males, Figure S10: Female patients showed poor separation based on the selected features by RFE, Table S1: Calculated migration time reproducibility of 2-AA labeled maltodextrin ladder, Table S2: Significant differences between control and PD patients.

Author Contributions: C.V. and J.B. designed and performed the experiments. O.H. and K.N. implemented the SVM-RFE. The main manuscript was written by C.V. and J.B. and extended by B.V.

Funding: This research was funded by the EU Framework Programme 7 under Marie Curie Actions, grants reference FP7-PEOPLE-2013-ITN-608381, and the GINOP-2.3.4-15-2016-00004 project. The APC was funded by the University of Miskolc.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. *Neurology* 2007, 68, 384–386. [CrossRef] [PubMed]
2. Dauer, W.; Przedborski, S. Parkinson’s disease: mechanisms and models. Neuron 2003, 39, 889–909. [CrossRef]
3. Marios, P.; Kit, W.; Sophie, M.; Peter, G.B.; Ray, C.K.; Paola, P. Parkinson’s disease symptoms: The patient’s perspective. Mov. Disord. 2010, 25, 1646–1651.
4. Chahine, L.M.; Stern, M.B. Diagnostic markers for Parkinson’s disease. Curr. Opin. Neurol. 2011, 24, 309–317. [CrossRef] [PubMed]
5. Jankovic, J. Parkinson’s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79, 368–376. [CrossRef] [PubMed]
6. Gornik, O.; Lauc, G. Glycosylation of serum proteins in inflammatory diseases. Dis. Markers 2008, 25, 267–278. [CrossRef] [PubMed]
7. Stowell, S.R.; Ju, T.; Cummings, R.D. Protein Glycosylation in Cancer. Annu. Rev. Pathol. 2015, 10, 473–510. [CrossRef] [PubMed]
8. Russell, A.C.; Simurina, M.; Garcia, M.T.; Novokmet, M.; Wang, Y.; Rudan, I.; Campbell, H.; Lauc, G.; Thomas, M.G.; Wang, W. The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson’s disease. Glycobiology 2017, 27, 501–510. [CrossRef] [PubMed]
9. Wuhrer, M. Glycosylation profiling in clinical proteomics: heading for glycan biomarkers. Expert Rev. Proteomics 2007, 4, 135–136. [CrossRef] [PubMed]
10. Mariño, K.; Bones, J.; Kattla, J.J.; Rudd, P.M. A systematic approach to protein glycosylation analysis: a path through the maze. Nat. Chem. Biol. 2010, 6, 713.
11. Gennaro, L.A.; Salas-Solano, O. On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies. Anal. Chem. 2008, 80, 3838–3845. [CrossRef] [PubMed]
12. Preißler, J.; Yeung, E.S. Characterization of Nonbonded Poly(ethylene oxide) Coating for Capillary Electrophoresis via Continuous Monitoring of Electroosmotic Flow. Anal. Chem. 1996, 68, 2885–2889. [CrossRef] [PubMed]
13. Haselberg, R.; Brinks, V.; Hawe, A.; de Jong, G.J.; Somsen, G.W. Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals. Anal. Bioanal. Chem. 2011, 400, 295–303. [CrossRef] [PubMed]
14. Wong, J.W.; Cagney, G. An overview of label-free quantitation methods in proteomics by mass spectrometry. Methods Mol. Biol. 2010, 604, 273–283. [PubMed]
15. Guyon, I.; Weston, J.; Barnhill, S.; Vapnik, V. Gene Selection for Cancer Classification using Support Vector Machines. Learn. 2002, 46, 389–422.
16. Zhang, F.; Kaufman, H.L.; Deng, Y.; Drabier, R. Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood. BMC Med. Genomics 2013, 6, S4. [CrossRef] [PubMed]
17. Varadi, C.; Mittermayr, S.; Millan-Martin, S.; Bones, J. Quantitative twoplex glycan analysis using (12)C6 and (13)C6 stable isotope 2-aminobenzoic acid labelling and capillary electrophoresis mass spectrometry. Anal. Bioanal. Chem. 2016, 408, 8691–8700. [CrossRef] [PubMed]
18. Harvey, D.J.; Merry, A.H.; Royle, L.; Campbell, M.P.; Dwek, R.A.; Rudd, P.M. Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 2009, 9, 3796–3801. [CrossRef] [PubMed]
19. Frenkel-Pinter, M.; Shmueli, M.D.; Raz, C.; Yanku, M.; Zilberzwige, S.; Gazit, E.; Segal, D. Interplay between protein glycosylation pathways in Alzheimer’s disease. Sci. Adv. 2017, 3, e1601576. [CrossRef] [PubMed]

Sample Availability: Samples of the compounds are not available from the authors.